In an 18‑year‑old woman with recurrent bacterial vaginosis and Candida vulvovaginitis, how should the labs (HbA1c 5.6 %, fasting glucose 107 mg/dL, alkaline phosphatase 122 U/L, AST 38 U/L, ALT 60 U/L, anion gap 6) be interpreted and managed?

Lab Interpretation and Management

These labs reveal prediabetes (HbA1c 5.6%, fasting glucose 107 mg/dL) and mild hepatic enzyme elevation (ALT 60 U/L), both of which require intervention given their direct contribution to recurrent vulvovaginal infections in this young woman.

Glucose Metabolism Abnormalities

The combination of HbA1c 5.6% (prediabetes range: 5.7-6.4%) and fasting glucose 107 mg/dL (impaired fasting glucose: 100-125 mg/dL) indicates impaired glucose tolerance, which is critically important in this clinical context.

Direct Link to Recurrent Candidiasis

• Women with recurrent vulvovaginal candidiasis have discretely impaired glucose tolerance even when not overtly diabetic 1. In a controlled study, 36% of women with recurrent VVC had at least one glucose concentration above the 95th percentile versus only 12% of controls, with significantly higher glucose levels at 0,30, and 60 minutes post-glucose load 1.

• The mechanism involves elevated blood glucose after sugar ingestion creating a vaginal environment conducive to Candida overgrowth 2. Additionally, specific immune aberrations (elevated Th2 response, blunted Th1 response) lead to tolerance and chronic low-grade infection with frequent exacerbations 2.

• Glycosylated hemoglobin was 25% higher in women with recurrent VVC (5 vs 4 g/dL), even after correcting for BMI 1, confirming chronic glucose dysregulation as a pathogenic factor.

Management of Glucose Abnormalities

Tight glycemic control is crucial and should be addressed immediately:

• Refer to endocrinology or initiate lifestyle modifications (diet, exercise, weight management if BMI elevated)
• Consider metformin for prediabetes management
• 24-hour glycemic control is essential for breaking the cycle of recurrent candidiasis 2
• Recheck fasting glucose and HbA1c in 3 months

Hepatic Enzyme Elevation

ALT 60 U/L (mild elevation, typically normal <40 U/L) with AST 38 U/L and alkaline phosphatase 122 U/L warrants investigation:

Differential Considerations

• Medication-induced hepatotoxicity: If she's been on recurrent or prolonged antifungal therapy (particularly oral azoles like fluconazole), this could explain the transaminitis
• Non-alcoholic fatty liver disease (NAFLD), especially if associated with insulin resistance/prediabetes
• Other causes: viral hepatitis, autoimmune hepatitis, alcohol use

Management Approach

• Obtain complete hepatic panel including GGT, bilirubin, albumin, PT/INR
• Screen for viral hepatitis (Hep B surface antigen, Hep C antibody)
• Review all medications, particularly any chronic fluconazole use
• If on maintenance fluconazole for RVVC, consider dose adjustment or alternative antifungal strategies given potential hepatotoxicity
• Ultrasound liver if NAFLD suspected
• Recheck LFTs in 4-6 weeks

Critical Pathophysiologic Link: BV-VVC Interrelationship

The recurrent bacterial vaginosis is likely the primary driver of recurrent candidiasis 3. This is a crucial clinical insight often missed:

• BV dysbiosis compromises immune defenses, neutralizing vaginal yeast tolerance and creating a proinflammatory environment that predisposes to consecutive VVC episodes 3
• Mixed infections occur in >90% of patients with long-standing recurrent vaginitis 4
• Recurrent BV and repeated antimicrobial exposure predispose to acquired fluconazole resistance in C. albicans, contributing to refractory VVC 3

Treatment Strategy for Dual Infection

Dual antimicrobial therapy is required initially 4:

1. Treat BV first or simultaneously: Metronidazole 500 mg PO BID × 7 days or metronidazole gel 0.75% intravaginally × 5 days
2. Treat VVC: Fluconazole 150 mg PO × 1 dose (if no hepatotoxicity concern) OR topical azole (miconazole, clotrimazole) × 7 days

Long-term Suppressive Therapy

Given recurrent nature (≥3 episodes in 12 months defines RVVC 5):

For RVVC maintenance 5, 6:

• Fluconazole 150 mg PO weekly × 6 months (individualized, decreasing doses per ReCiDiF regimen 7)
• However, given ALT elevation, consider topical maintenance therapy instead or monitor LFTs monthly if using oral fluconazole
• Alternative: Vaginal boric acid 600 mg suppositories daily × 14 days, then twice weekly for maintenance (especially if fluconazole resistance suspected 8)

For RBV prevention 8:

• Consider vaginal Lactobacillus crispatus products for BV prevention after initial treatment
• Metronidazole gel 0.75% twice weekly × 4-6 months as suppressive therapy

Anion Gap 6

This is low-normal (normal range typically 8-12 mEq/L). Low anion gap is generally not clinically significant in this context but can be seen with:

• Hypoalbuminemia (check albumin level)
• Laboratory error
• Multiple myeloma (unlikely in 18-year-old)

No immediate action required unless albumin is low, which would warrant further investigation.

Common Pitfalls to Avoid

1. Treating VVC alone without addressing BV - this perpetuates the cycle 3
2. Ignoring glucose dysregulation - this is a modifiable risk factor directly contributing to recurrence 2, 1
3. Continuing oral fluconazole without monitoring LFTs - hepatotoxicity risk, especially with maintenance therapy
4. Assuming treatment failure is due to non-compliance rather than fluconazole resistance (occurs in 10-15% of recurrent cases 9) or reinfection from untreated partner
5. Not obtaining fungal culture with species identification in recurrent cases 6 - non-albicans species require alternative antifungals

Immediate Action Items

1. Address prediabetes with lifestyle modification ± metformin
2. Investigate ALT elevation (viral hepatitis screen, medication review, consider imaging)
3. Treat both BV and VVC simultaneously with dual therapy
4. Obtain vaginal culture with Candida species identification and susceptibility testing
5. Initiate long-term suppressive therapy for both conditions after acute treatment
6. Recheck labs (glucose, HbA1c, LFTs) in 3 months